Oracle Alpha’s Relay Therapeutics RLAY Stock Holding History

Oracle Alpha’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-18,716	Closed	-$206K	–	251
2023 Q4	$206K	Buy	+18,716	New	+$158K	0.27%	184

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Oracle Alpha's RLAY Position: Q1 2024 in Review

Oracle Alpha sold out of Relay Therapeutics (RLAY) in Q1 2024, closing a stake of 18,716 shares — an estimated $206K sold.

Oracle Alpha first reported a position in RLAY in Q4 2023 and held it in 1 quarter. The position peaked at $206K in Q4 2023. 189 funds tracked by Wall St. Rank hold RLAY as of Q1 2024.

Oracle Alpha reported no remaining Relay Therapeutics position as of Q1 2024 after selling out during the quarter.
Oracle Alpha sold 18,716 Relay Therapeutics shares in Q1 2024, an estimated $206K.
Oracle Alpha first reported a position in Relay Therapeutics in Q4 2023 and held it in 1 quarter.
Oracle Alpha's Relay Therapeutics position peaked at $206K in Q4 2023.
189 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2024.

Based on Oracle Alpha's 13F filing for Q1 2024, filed 15 May 2024.